Advertisement

Topics

iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations

20:00 EDT 14 Mar 2017 | PharmaTelevision

iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.

Original Article: iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations

NEXT ARTICLE

More From BioPortfolio on "iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...